Emergent BioSolutions Facing Securities Class Action Over Vaccine Manufacturing Woes, Stock Drops
June 3, 2021 COVID-19 vaccine manufacturer Emergent BioSolutions faces a securities class action over "misrepresentations and omissions" about quality control problems at its Baltimore facility.